These malignancies are also known as double-hit (MYC/BCL2 or MYC/BCL6 translocations) and triple-hit (MYC/BCL2/BCL6 translocations) lymphomas (DHL/THL), and represent 5–10% of DLBCL patients [20,21]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.